Clinical Research Directory

Inclusion Criteria: * Parent/Guardian able to provide written informed consent * Within 6 weeks of discharge from hospital for bronchiolitis * Child aged ≥2 weeks and ≤12 months at the time of consent to study * A diagnosis of Bronchiolitis requiring a hospital admission (defined as more than 4 hours in hospital) * Contactable for regular follow up by the research team Exclusion Criteria: * Any previous hospital attendance for bronchiolitis * More than one episode of healthcare professional-diagnosed wheeze prior to index bronchiolitis episode * Premature gestational age less than 37 weeks * Any severe chronic condition such as cystic fibrosis, sickle cell disease, severe developmental delay, immunodeficiency, or anything that has a significant impact on the respiratory tract (such as need for non-invasive ventilation) or increases vulnerability to respiratory tract infections. * History of clinically significant neonatal disease (e.g. neonatal pneumonia, congenital lung abnormality, neonatal chronic lung disease) * Genetic conditions that affect the immune system (e.g. Down's syndrome/Trisomy 21) * Current regular oral montelukast or inhaled corticosteroid therapy or inhaled salbutamol therapy * Current regular treatment with immunomodulatory drugs (e.g oral steroids) * Known allergy or previous intolerance to study medication. * Currently enrolled to another Randomised Clinical Trial. (Unless prior approval is given by Principal Investigator) * Sibling of a BLIPA participant (of the same household or family)